

MOLDX: BIOMARKER RISK STRATIFICATION TESTING IN DCIS

Bibliography

1. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. *Breast Cancer Res Treat.* 2007;101(3):335-347. doi:10.1007/s10549-006-9302-0
2. Sagara Y, Freedman RA, Wong SM, et al. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. *Breast Cancer Res Treat.* 2017;166(2):583-592. doi:10.1007/s10549-017-4436-9
3. Giannakeas V, Sopik V, Narod SA. Association of radiotherapy with survival in women treated for ductal carcinoma In situ with lumpectomy or mastectomy *JAMA Netw Open.* 2018;1(4):e181100. doi:10.1001/jamanetworkopen.2018.1100
4. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. *Cancer.* 1996;77(11):2267-2274. doi:10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V
5. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. *N Engl J Med.* 1999;340(19):1455-1461. doi:10.1056/NEJM199905133401902
6. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. *Lancet.* 2019;394(10215):2155-2164. doi:10.1016/S0140-6736(19)32514-0
7. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. *J Clin Oncol.* 2009;27(32):5319-5324. doi:10.1200/JCO.2009.21.8560
8. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. *Ann Surg.* 2015;262(4):623-631. doi:10.1097/SLA.0000000000001454
9. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy. *Breast.* 2018;37:181-186. doi:10.1016/j.breast.2017.07.002

10. Rakovitch E, Nofech-Mozes S, Narod SA, et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. *Breast Cancer Res Treat.* 2013;138(2):581-590. doi:10.1007/s10549-013-2455-8
11. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. *J Natl Cancer Inst.* 2017;109(4):djw256. doi:10.1093/jnci/djw256
12. Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. *Breast Cancer Res Treat.* 2015;152(2):389-398. doi:10.1007/s10549-015-3464-6
13. Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. *Clin Cancer Res.* 2018;24(23):5895-5901. doi:10.1158/1078-0432.CCR-18-0842
14. Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. *Clin Cancer Res.* 2018;24(23):5895-5901. doi:10.1158/1078-0432.CCR-18-0842
15. Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. *Breast Cancer Res Treat.* 2018;169(2):359-369. doi:10.1007/s10549-018-4693-2
16. Weinmann S, Leo MC, Francisco M, et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy. *Clin Cancer Res.* 2020;26(15):4054-4063. doi:10.1158/1078-0432.CCR-19-1152
17. Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-Year results from the ECOG-ACRIN E5194 study. *J Clin Oncol.* 2015;33(33):3938-3944. doi:10.1200/JCO.2015.60.8588
18. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. *Eur J Cancer.* 2007;43(2):291-298. doi:10.1016/j.ejca.2006.09.018
19. McCormick B, Winter KA, Woodward W, et al. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG Oncology/RTOG 9804. *J Clin Oncol.* 2021;39(32):3574-3582. doi:10.1200/JCO.21.01083
20. Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal

carcinoma in situ: a population-based longitudinal cohort study. *J Clin Oncol.* 2016;34(11):1190-1196. doi:10.1200/JCO.2015.65.1869

21. Van Zee KJ, Zabor EC, Di Donato R, et al. Comparison of local recurrence risk estimates after breast-conserving surgery for DCIS: DCIS nomogram versus refined Oncotype DX Breast DCIS Score. *Ann Surg Oncol.* 2019;26(10):3282-3288. doi:10.1245/s10434-019-07537-y

22. Wörnberg F, Karlsson P, Holmberg E, et al. Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS). *Cancers (Basel).* 2021;13(23):6103. doi:10.3390/cancers13236103

23. Dabbs D, Mittal K, Heineman S, et al. Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ. *Front Oncol.* 2023;13:1069059. doi:10.3389/fonc.2023.1069059

24. Shah C, Whitworth P, Vicini FA, et al. The clinical utility of a 7-gene biosignature on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery: an updated analysis of the DCISionRT® PREDICT study. *Ann Surg Oncol.* Published online June 25, 2024. doi:10.1245/s10434-024-15566-5

25. Rabinovitch R, Vicini F, Shah C, et al. 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy. *Cancer Res.* 2023;1;83(5 Suppl):PD15-07. doi:10.1158/1538-7445.SABCS22-PD15-07

26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr.* 2010;2010(41):162-177. doi:10.1093/jncimonographs/lgq039

27. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. *J Clin Oncol.* 2010;28(23):3762-3769. doi:10.1200/JCO.2009.26.8847

28. Collins LC, Achacoso N, Haque R, et al. Risk prediction for local breast cancer recurrence among women with DCIS treated in a community practice: a nested, case-control study. *Ann Surg Oncol.* 2015;22 Suppl 3:S502-S508. doi:10.1245/s10434-015-4641-x

29. Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. *Ann Surg Oncol.* 2015;22(10):3273-3281. doi:10.1245/s10434-015-4740-8

30. Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. *Ann Surg Oncol.* 2015;22(10):3273-3281. doi:10.1245/s10434-015-4740-8